The therapeutic scope of Бутадион (Phenylbutazone) is applied across domains where additional symptomatic support is needed.

The primary application includes the symptomatic management of inflammatory conditions associated with the musculoskeletal system in horses. The medication is generally used to help provide supportive relief from the pain, swelling, and tenderness associated with acute and chronic inflammatory conditions of the joints, muscles, and soft tissues. These conditions often include osteoarthritis and injuries, providing support that helps ease the overall symptom burden, especially during episodes of sudden symptom escalation.

---

Symptomatic Support Domains

This medication is relevant for easing symptom clusters that may become intense or disruptive, such as those related to musculoskeletal inflammation, restricted mobility (e.g., lameness), and acute rheumatic pain. In humans, this drug is reserved for the short-term support of specific, often severe rheumatic disorders in highly selected patients, such as acute gouty arthritis. This approach is generally used in clinical settings that involve acute or unstable symptom patterns, helping patients cope more steadily with difficult episodes.

“This medication is applied in situations where additional symptomatic support is needed to address pronounced symptoms that interfere with daily functioning.”

Quick Fact: Relief for Inflammation-Induced Pain The primary use supports the management of conditions presenting with systemic or localized discomfort linked to inflammatory processes, particularly in veterinary and reserved human clinical contexts.

Regulatory References

1. FDA-approved veterinary product indications

Eligibility Map: Who can and cannot use Бутадион — Official Regulatory Information

The eligibility profile for Бутадион (Phenylbutazone) is defined primarily by absolute exclusions due to severe safety risks, resulting in its withdrawal or highly restricted status for human use in most major markets. The medicine is reserved for a highly selected adult patient population for specific, severe conditions, typically only after other treatments have failed and under specialist care.

---

Eligibility Scope

Populations for whom use is contraindicated:

• Patients with evidence of, or a history of, blood dyscrasia (e.g., aplastic anemia).
• Patients with known hypersensitivity to Phenylbutazone.
• Patients suffering from active gastro-intestinal ulceration or bleeding.
• Patients with severe cardiac, hepatic (liver), or renal (kidney) disease.

Age-related eligibility rules:

• Pediatric Population: Approved use is not established in children or adolescents.

Pregnancy and lactation eligibility status:

• Pregnancy: Safety is not established. Use should be avoided whenever possible, particularly during the first trimester.

---

Connection to the Overall Eligibility Profile

Official regulatory documents define who can use the medicine by first establishing a comprehensive framework of absolute contraindications related to organ integrity, blood health, and gastrointestinal risk. This framework severely limits eligibility, reserving the drug only for the narrow subset of adult patients who do not meet any of the exclusion criteria and whose specific, resistant condition warrants its restricted application.

Interactions with other medicines and products

Butadion (Phenylbutazone) interacts with co-administered medicines primarily through two pharmacokinetic pathways: competition for plasma protein binding and inhibition of drug metabolism. This activity leads to specific constraints documented in official regulatory labeling.

Interaction Type	Interacting Substance	Official Regulatory Outcome
Prohibited Combination	Other NSAIDs	Must not be administered concurrently or within 24 hours due to severe additive gastrointestinal risk.
Pharmacodynamic Risk	Corticosteroids	Increased risk of gastrointestinal ulceration and hemorrhage.
Substance Warning	Alcohol (Ethanol)	May increase the risk of liver problems (hepatotoxicity).

The drug is highly protein-bound and can displace agents like Sulfonylurea antidiabetic agents or Coumarin anticoagulants (e.g., Warfarin), leading to an increase in active, non-bound concentrations. This effect may result in enhanced outcomes for the co-administered drug, such as hypoglycemia or increased bleeding risk, requiring careful patient monitoring.

Furthermore, Butadion can reduce the clearance of substances like Phenytoin and Warfarin by inhibiting their hepatic metabolism, which leads to elevated serum levels of these medications. Official warnings also note that special caution is required for aged patients and those with dehydration, as the risk of interaction-related complications is increased in these populations.

How Бутадион Works

Primary Action: Non-Selective Enzyme Inhibition The core mechanism of Phenylbutazone (Бутадион) is the competitive and non-selective inhibition of both the Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. This action blocks the initial step in the Arachidonic Acid Cascade, thereby reducing the synthesis of key signaling molecules known as Prostanoids (Prostaglandins, Thromboxanes, and Prostacyclin). This molecular interference leads directly to the reduction of nociceptor sensitization and vascular permeability at the tissue level.

---

Systemic Modulation of Thermoregulatory Signals The mechanism extends to the central nervous system, where the drug reduces the production of Prostaglandin E2 ( PGE2) within the hypothalamus. This specific chemical reduction reverses the signal for the elevated temperature set point that is triggered during a febrile state. The physiological consequence is a signal that promotes heat loss, contributing to the adjustment of the elevated core body temperature.

---

️ Secondary Stabilisation of Inflammatory Components Phenylbutazone possesses a complementary mechanism independent of COX inhibition, involving the stabilization of internal cellular membranes, particularly the lysosomes within inflammatory cells. The mechanism modulates the release of degradative enzymes from these cells, influencing the local chemical environment associated with the inflammatory response.

How to Use Бутадион (Phenylbutazone): Administration Guidelines

The usage of Бутадион (Phenylbutazone) follows specific administration practices, which primarily address its use in veterinary medicine. The medicine is administered through two routes: oral (using tablets, capsules, powders, or pastes) and intravenous (IV) injection. Standard practice excludes the use of Phenylbutazone via subcutaneous (SC) or intramuscular (IM) injection due to the risk of severe local tissue reactions.

Dosing and Scheduling Principles

Administration follows a structured, weight-based approach. Doses, calculated in grams based on body weight, are subject to a maximum daily limit. For the oral route, the total daily dose is typically divided into two or three separate administrations to manage systemic levels. Intravenous administration is generally performed once daily.

Treatment duration is carefully managed. Application involves the use of a higher starting dose for the first 48 hours, which is then progressively reduced to the lowest amount that maintains the desired clinical response. Furthermore, the use of the injectable IV form is limited to a maximum of five successive days, requiring a transition to the oral form if therapy needs to be continued.

Contextual Requirements for Use

Oral preparations are administered with or immediately after food or mixed with feed to ensure proper intake and drug tolerability. Conversely, the IV solution is administered slowly and carefully directly into a vein. While caution is noted in young subjects (foals), there are no established numerical dose adjustments for human populations (pediatric/geriatric) due to the drug’s restricted status.

---

Research Evidence / Overview of Studies for Бутадион (Phenylbutazone)

---

Research Evidence for Equine Musculoskeletal Conditions

The most extensive modern research for Phenylbutazone was studied in the context of musculoskeletal conditions in horses. This evidence is relevant in trials assessing short-term or episodic symptom patterns linked to conditions like lameness and osteoarthritis. Researchers primarily used short-term Randomized Controlled Trials (RCTs) and controlled field studies.

These studies monitored several key factors, including changes in lameness severity (using both subjective clinical scoring and objective tools) and the presence of localized swelling and tenderness. The findings describe patterns observed in the studies where measurements of lameness scores reflected changes over the short study period. However, the long-term follow-up durations were limited in many of the studies. Therefore, long-term effects are not fully established, particularly concerning the progression of chronic conditions like osteoarthritis.

---

Historical Evidence for Restricted Human Rheumatic Disorders

In the human context, Бутадион was studied for its application in conditions characterized by fluctuating or episodic manifestations, such as acute gouty arthritis and, historically, certain severe forms of rheumatoid arthritis. The research base here is largely composed of historical Controlled Clinical Trials conducted decades ago. These studies explored outcomes related to physical discomfort, focusing on short-term changes.

These older trials monitored measurements of symptom variability and mobility metrics during the acute phases of treatment. Findings describe patterns where the medication was studied in the context of short-term changes during periods of increased symptom activity.

Crucially, evidence is limited for modern comparative use, as the majority of current data show patterns related to the drug’s significant safety profile, which has led to severe regulatory restrictions and withdrawal from most markets. Therefore, certainty remains low when applying these historical findings to current standards of care.

---

Evidence Gaps and Areas of Scientific Uncertainty

The research landscape for Бутадион presents several areas of scientific uncertainty. As much of the human data is historical, evidence quality varies across studies, and many do not meet current clinical research standards. Furthermore, comparative evidence is lacking against most modern anti-inflammatory treatments used today. Overall, the available evidence contributes to understanding that studies were conducted during periods of increased symptom activity—and what is still uncertain, particularly regarding long-term safety, durability, and findings in populations beyond the narrowly studied groups. The findings describe group patterns, not personal outcomes.

Key Studies & References FDA-Approved Labeling and Indications for Phenylbutazone Injectable Solution (Equine)

Common questions about Бутадион (FAQ)

---

Q: Is Бутадион safe to use for a long period of time?

Regulatory warnings describe that the risk of serious adverse reactions, particularly severe blood disorders (blood dyscrasias), increases with the duration of treatment. Official administration guidelines indicate that use should be limited to the lowest effective amount for the shortest duration possible.

---

Q: Does taking Бутадион affect the results of any lab tests?

Official information indicates that this medication and its breakdown products (metabolites) can remain in the body for a prolonged period. The presence of these substances may interfere with the analysis and results of certain laboratory tests, particularly those designed to detect other drugs in the blood or urine.

---

Q: Why do doctors check liver enzymes when a patient is on Бутадион?

The official product warnings highlight the potential for severe hepatic reactions, which include fatal hepatitis and jaundice. Monitoring is conducted as a measure to detect these serious, documented risks.

---

Q: How quickly does Бутадион usually start working after the first dose?

Official information regarding the clinical response notes that the onset of the clinical response is generally prompt when the medication is administered. This effect is typically observed within 24 hours following the initial dose.

---

Q: How long do the effects of Бутадион typically last?

Studies and official information describe that the clinical response is commonly observed to last for approximately 48 hours after the final administration. The clinical effect can be evident for at least three days following cessation.

---

Q: Is it normal to feel tired or dizzy when first starting Бутадион?

Official warnings from historical human product information listed potential nervous system-related side effects, including feelings of lightheadedness, vertigo, and potential changes in mental state. These symptoms are characteristic of those listed in the drug's historical side effect profile.

---

Q: Does Бутадион affect the liver, and if so, how?

Yes, official regulatory documents list the potential for severe hepatic reactions, which may include fatal hepatitis and jaundice. This is noted as one of the critical safety components officially associated with the drug.

---

Q: Can older adults safely use Бутадион?

Official product information describes the need for caution in older populations. Historical product warnings specifically noted that elderly, frail, and debilitated patients are documented as being at a higher risk for adverse reactions, including renal complications.

---

Q: Can a person stop taking Бутадион suddenly?

Regulatory guidance describes that discontinuance of treatment for chronic conditions may result in the recurrence of the original symptoms. This is the primary expectation upon cessation.

---

Q: Are there any warnings about using Бутадион before surgery?

Yes, official guidance advises that this drug should be discontinued prior to elective surgery. This advice is given due to the drug's characteristics as an NSAID, a class known to interact with blood clotting processes.

---

Q: Does Бутадион cause drowsiness or affect driving?

Although not specifically labeled as a sedative, the documented side effect profile included symptoms such as vertigo, lightheadedness, and mental disturbances. Patients experiencing these effects should exercise caution regarding activities that require alertness, such as driving.

---

Q: What should I do if I miss a dose of Бутадион?

Official labels generally indicate that if a dose is missed, it is often administered as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Official guidelines strictly state that double dosing is not permitted.

---

Q: Is the medication still effective if I take it with food?

Official guidelines recommend taking the drug with or immediately after food, which is intended to help ensure proper intake and drug tolerability. This administration condition is part of the established usage protocol.

---

Q: Are there any age restrictions for taking Бутадион?

Official information for the human formulation previously contra-indicated the drug for children fourteen years of age or less. Its approved use in children and adolescents is generally not established.

---

Q: Are there different strengths or forms of Бутадион available?

According to official drug overviews, this medication is available in several forms. These include oral tablets or capsules, and a liquid injectable solution for parenteral use. Various strengths are officially documented.

---

Q: Why is a prescription required for Бутадион?

The product is classified as prescription-only due to its significant toxicity profile and the necessity for close medical supervision. Regulatory labeling strictly restricts its use to being by or on the order of a licensed professional.

---

Q: How does the body generally clear Бутадион?

Pharmacokinetic data indicates that the drug is nearly completely metabolized by the body's systems. It is primarily broken down into active substances, such as Oxyphenbutazone, and is then eliminated from the body, mostly through the urine.

---

Q: Is Бутадион used outside of treating inflammation and pain?

Official labeling classifies this compound as an anti-inflammatory and antipyretic (fever-reducing) agent. Any pain relief achieved by the drug is described as primarily related to its direct anti-inflammatory properties.

---

Q: Are there any major diet restrictions while using Бутадион?

The only major substance explicitly warned against in regulatory documents is alcohol (ethanol). Concurrent use may increase the documented risk of serious liver problems (hepatotoxicity). No other specific major diet restrictions are detailed in the official warnings.

---

Q: Is there a risk of dependency or addiction with Бутадион?

Historical official product information specifically describes Phenylbutazone as being not habit forming. This designation indicates that the drug is not associated with a risk of dependency or addiction.

---

Q: Can this medicine be used for muscle strains or injuries?

The official labeling describes the drug's use for managing inflammatory conditions associated with the musculoskeletal system, which includes issues affecting joints and soft tissues like muscle strains and related injuries.

---

Q: Is Бутадион useful for treating gout attacks?

Historical clinical evidence describes that the medication was studied for conditions including acute gouty arthritis in humans, alongside various other rheumatoid disorders.

---

Q: Why is this drug sometimes called by a different name?

The name Бутадион is a recognized trade name for the single active substance contained in the medication, which is Phenylbutazone. The drug has also been known by other former trade names, such as Butazolidin.

---

Q: Why is Бутадион sometimes prescribed instead of other common anti-inflammatory drugs?

Official regulatory guidelines indicate that, due to its significant toxicity profile, the drug is intended for a highly selected adult patient population. Its use is typically limited to specific, severe conditions, often only after other, less restricted treatments have failed.

Official Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of Butadion (Phenylbutazone) to maintain its stability and ensure safety.

Storage Conditions

Requirement	Classification
Temperature	Store at room temperature, or alternatively, refrigerated between 2 C and 8 C (36 F and 46 F).
Protection	Keep in a closed container and protect strictly from moisture. Avoid storage near strong oxidizing agents, heat, flames, and sparks.
Handling	Minimize the generation of dust and use adequate ventilation; avoid breathing the dust and prevent contact with skin and eyes.

Disposal Rules

When disposing of unused Butadion, follow specific instructions on the labeling or utilize a community drug take-back program. If a take-back program is unavailable, mix the medicine with an undesirable substance (such as used coffee grounds) and place the mixture in a sealed container before discarding in household trash. Disposal must be conducted according to local and national regulations, and release into the environment should be avoided.